MedImmune MEDI
-
New Morningstar Analyst Report - AstraZeneca PLC ADR
… 14 billion in additional debt due to the MedImmune acquisition in 2007 still exhibits some ..... the $15.6 billion price tag paid for MedImmune in 2007 appears too high. Several of MedImmune 's early-stage products need to achieve …
-
GS insider trading probe aimed at healthcare tips
* Tips eyed on deals for Advanced Medical Optics, MedImmune
-
Amgen And AstraZeneca To Collaborate On Inflammation Portfolio
… will provide Amgen with new money to progress its portfolio and new development expertise in inflammation and asthma from MedImmune , AstraZeneca's biologics arm, the companies say. AstraZeneca will lead the development and commercial strategy for AMG …
-
Shorting Candidate AstraZeneca
… time until 2014 to develop its pipeline and it is lowering risk on the future earnings stream. The company has digested the MedImmune acquisition. Brilinta (thrombosis) is the biggest potential blockbuster for Astra, but competition from Plavix generics …
-
SAC faces insider trading probe on MedImmune : report
(Reuters) - SAC Capital Advisors LP faces an insider trading probe from the U.S. Securities and Exchange Commission related to the $15 billion takeover of biotechnology firm MedImmune Inc, the Wall Street Journal reported, citing people familiar with the matter.
-
SAC Capital Advisors is said to be a focus of an SEC investigation into whether traders used insider information to profit from the 2007 takeover of MedImmune . It wasn't previously known whether SAC ...
… said to be a focus of an SEC investigation into whether traders used insider information to profit from the 2007 takeover of MedImmune . It wasn't previously known whether SAC was a target of the probe, though it is the subject of two other inquiries . Post …
-
SAC faces insider trading probe on MedImmune -WSJ
June 1 (Reuters) - SAC Capital Advisors LP faces an insider trading probe from the U.S. Securities and Exchange Commission related to the $15 billion takeover of biotechnology firm MedImmune Inc, the...
-
New Morningstar Analyst Report - Auxilium Pharmaceuticals
… qualified for a company of Auxilium's size ; Anido previously served as head of sales and marketing for biotech company MedImmune , now a part of AstraZeneca AZN , where he managed strategy and commercialization of branded products . Auxilium Pharmaceuticals …
-
Auxilium Pharmaceuticals is nearing approval for XIAFLEX for rare conditions.
… qualified for a company of Auxilium's size; Anido previously served as head of sales and marketing for biotech company MedImmune , now a part of AstraZeneca AZN, where he managed strategy and commercialization of branded products.Auxilium Pharmaceuticals …
-
Milestones Help Medarex's Top Line
… our fair value estimate until we see positive late-stage clinical results from its drugs. In August, Medarex's partner MedImmune initiated a Phase IIa trial of MEDI-545 for systemic lupus erythematosus. As MEDI-545 was discovered using Medarex …